BioXcel Therapeutics Community

NasdaqCM:BTAI Community

1 Narratives written by author
0 Comments on narratives written by author
7 Fair Values set on narratives written by author

BioXcel Therapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

BXCL501 And SERENITY Trials Will Unlock New Treatment Horizons

Key Takeaways Advancing Phase III trials and successful SERENITY outcomes could expand market access and boost revenue through FDA approvals and new partnerships. Cost reduction initiatives and strategic financing strengthen financial stability, improving margins and enabling further commercialization efforts.

US$36.25

FV

95.3% undervalued

198.06%

Revenue growth p.a.

0

0

6

Updated